Fluent

Fluent EBITDA

Delisted

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Fluent (TIUM.U.CN) as of Nov 5, 2026 is 31.28 M USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 19.26 M USD — a change of 62.42% (higher).

EBITDA

31.28 MUSD

YoY

62.42%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Fluent is 2023 31.28 M USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Fluent was 2022 19.26 M USD. It decreases by 62.42% higher compared to the previous year.

The Fluent EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
0.00 USD
Jan 1, 2019
-32.73 M USD
Jan 1, 2020
-19.76 M USD
Jan 1, 2021
-9.11 M USD
Jan 1, 2022
19.26 M USD
Jan 1, 2023
31.28 M USD
The Fluent EBITDA history
YEAREBITDAYoY
31.28 MUSD+62.42%
19.26 MUSD-311.37%
-9.11 MUSD-53.88%
-19.76 MUSD-39.63%
-32.73 MUSD—
0.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Fluent Stock analysis

What does Fluent do? Fluent Corp operates under the private label Fluent, selling medical cannabis products in Florida, Texas, and Pennsylvania. The company's products include oral drops, capsules, suppositories, topicals, syringes, dried flower, pre-rolls, cartridges, edibles, and accessories. Subsidiaries such as Cansortium Holdings LLC and Cansortium Florida, LLC handle production and sales, while Fluent Servicing, LLC manages servicing aspects. The company's revenue comes from direct sales of medical cannabis products through its licensed operations in multiple states. Fluent Corp's target customers are patients seeking medical cannabis treatments, with products tailored to various consumption methods. The company leverages its subsidiaries to maintain compliance and expand its market reach across different states. Sales are conducted through licensed dispensaries and medical cannabis programs, focusing on the healthcare segment of the cannabis industry. The business model relies on the production and sale of medical cannabis under the private label Fluent, utilizing subsidiaries to manage state-specific operations. Products are distributed through established medical cannabis channels, with no mention of additional revenue streams beyond product sales. The company's focus remains on the medical cannabis market, serving patients in Florida, Texas, and Pennsylvania. Fluent is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Fluent stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Fluent is 31.28 M USD in 2023.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Fluent changed from 19.26 M USD to 31.28 M USD, representing a 62.42% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Fluent since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Fluent historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Fluent

All Key Metrics — Fluent